Invention Grant
- Patent Title: Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
-
Application No.: US16741634Application Date: 2020-01-13
-
Publication No.: US11253560B2Publication Date: 2022-02-22
- Inventor: Liang Deng , Jedd Wolchok , Taha Merghoub , Stewart Shuman , Peihong Dai , Weiyi Wang
- Applicant: Memorial Sloan Kettering Cancer Center
- Applicant Address: US NY New York
- Assignee: Memorial Sloan Kettering Cancer Center
- Current Assignee: Memorial Sloan Kettering Cancer Center
- Current Assignee Address: US NY New York
- Agency: Foley & Lardner LLP
- Main IPC: A61K35/768
- IPC: A61K35/768 ; A61K39/395 ; C07K16/28 ; A61K39/12 ; A61K39/00
Abstract:
The present disclosure relates to modified vaccinia Ankara (MVA) virus or MVAΔE3L delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor.
Public/Granted literature
- US20200222479A1 USE OF MVA OR MVADELTAE3L AS IMMUNOTHERAPEUTIC AGENTS AGAINST SOLID TUMORS Public/Granted day:2020-07-16
Information query
IPC分类:
